KR20170118166A - 1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도 - Google Patents

1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도 Download PDF

Info

Publication number
KR20170118166A
KR20170118166A KR1020177025946A KR20177025946A KR20170118166A KR 20170118166 A KR20170118166 A KR 20170118166A KR 1020177025946 A KR1020177025946 A KR 1020177025946A KR 20177025946 A KR20177025946 A KR 20177025946A KR 20170118166 A KR20170118166 A KR 20170118166A
Authority
KR
South Korea
Prior art keywords
rti
alkyl
haloalkyl
cycloalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177025946A
Other languages
English (en)
Korean (ko)
Inventor
앤쏘니 에스트라다
매튜 볼그라프
후이펜 천
알렉산드르 콜레스니코프
엘리시아 빌무어
비샬 베르마
란 왕
다니엘 쇼어
스티븐 두
포-와이 위엔
바이후아 후
궈셩 우
싱위 린
아이쥔 루
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20170118166A publication Critical patent/KR20170118166A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65127—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177025946A 2015-02-15 2016-02-12 1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도 Withdrawn KR20170118166A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2015073102 2015-02-15
CNPCT/CN2015/073102 2015-02-15
CN2015076318 2015-04-10
CNPCT/CN2015/076318 2015-04-10
CNPCT/CN2016/071061 2016-01-15
CN2016071061 2016-01-15
PCT/EP2016/052950 WO2016128529A1 (en) 2015-02-15 2016-02-12 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists

Publications (1)

Publication Number Publication Date
KR20170118166A true KR20170118166A (ko) 2017-10-24

Family

ID=55349845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025946A Withdrawn KR20170118166A (ko) 2015-02-15 2016-02-12 1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도

Country Status (20)

Country Link
US (1) US10179782B2 (enExample)
EP (1) EP3256463B1 (enExample)
JP (1) JP6700291B2 (enExample)
KR (1) KR20170118166A (enExample)
CN (1) CN107922392B (enExample)
AU (1) AU2016217851A1 (enExample)
BR (1) BR112017017052A2 (enExample)
CA (1) CA2975196A1 (enExample)
CL (1) CL2017001987A1 (enExample)
CO (1) CO2017007679A2 (enExample)
CR (1) CR20170367A (enExample)
EA (1) EA033497B1 (enExample)
IL (1) IL253478A0 (enExample)
MX (1) MX2017010300A (enExample)
PE (1) PE20180177A1 (enExample)
PH (1) PH12017501478A1 (enExample)
PT (1) PT3256463T (enExample)
SG (1) SG11201706451TA (enExample)
TW (1) TW201639829A (enExample)
WO (1) WO2016128529A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
RS59512B1 (sr) 2012-09-25 2019-12-31 Hoffmann La Roche Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
WO2015078803A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
KR20160128428A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
SG10201902963PA (en) 2014-10-06 2019-05-30 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
CN107592861B (zh) * 2015-03-06 2021-06-08 法玛克亚公司 氟化赖氨酰氧化酶样2抑制剂及其用途
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
US20180186755A1 (en) * 2015-07-01 2018-07-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
KR102766396B1 (ko) * 2016-02-05 2025-02-13 이에이 파마 가부시키가이샤 복소환 술폰아미드 유도체 및 그것을 함유하는 의약
EP3487849A1 (en) 2016-07-20 2019-05-29 H. Hoffnabb-La Roche Ag Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
CN109476640B (zh) * 2016-07-20 2022-02-25 豪夫迈·罗氏有限公司 双环脯氨酸化合物
CN109803964A (zh) 2016-08-12 2019-05-24 豪夫迈·罗氏有限公司 磺酰基吡啶基trp抑制剂
WO2018048943A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
CN109922803B (zh) 2016-09-07 2023-09-22 法玛克亚公司 赖氨酰氧化酶样2抑制剂的用途
HUE052205T2 (hu) 2016-12-09 2021-04-28 Vertex Pharma Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
EP3554500A1 (en) 2016-12-16 2019-10-23 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
JP7101177B2 (ja) 2017-01-10 2022-07-14 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
CA3085006A1 (en) * 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AR114585A1 (es) 2018-02-20 2020-09-23 Hoffmann La Roche Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
CN110156834A (zh) * 2019-06-05 2019-08-23 镇江市高等专科学校 一种黄色荧光铜(i)配合物及其制备方法和应用
JP7471407B2 (ja) 2020-05-19 2024-04-19 ユニマテック株式会社 含フッ素ピリミジン化合物および含フッ素ピリミジノン化合物
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
CN116600787A (zh) * 2020-11-19 2023-08-15 阿库西亚医疗有限责任公司 非水性凝胶组合物
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
US20250064846A1 (en) * 2022-01-07 2025-02-27 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025155669A1 (en) * 2024-01-17 2025-07-24 The Jackson Laboratory Trpc3 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
EP2520566A1 (en) * 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP6182072B2 (ja) 2012-01-17 2017-08-16 Ｅａファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
JP6301842B2 (ja) * 2012-12-18 2018-03-28 Ｅａファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
US9394308B2 (en) * 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
TW201441225A (zh) * 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
EP3055302B1 (en) * 2013-10-11 2018-12-26 F. Hoffmann-La Roche AG Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
BR112016017317B1 (pt) 2014-01-28 2023-04-11 EA Pharma Co., Ltd Composto, e, uso de um composto

Also Published As

Publication number Publication date
EA033497B1 (ru) 2019-10-31
CR20170367A (es) 2017-09-12
CO2017007679A2 (es) 2017-10-20
EA201791836A1 (ru) 2017-12-29
PH12017501478A1 (en) 2018-01-29
EP3256463B1 (en) 2019-10-09
CN107922392B (zh) 2020-07-21
PT3256463T (pt) 2019-12-05
MX2017010300A (es) 2017-12-04
WO2016128529A1 (en) 2016-08-18
PE20180177A1 (es) 2018-01-22
HK1251815A1 (zh) 2019-03-29
JP2018513107A (ja) 2018-05-24
EP3256463A1 (en) 2017-12-20
CN107922392A (zh) 2018-04-17
SG11201706451TA (en) 2017-09-28
CL2017001987A1 (es) 2018-08-24
JP6700291B2 (ja) 2020-05-27
CA2975196A1 (en) 2016-08-18
BR112017017052A2 (pt) 2018-04-10
IL253478A0 (en) 2017-09-28
TW201639829A (zh) 2016-11-16
AU2016217851A1 (en) 2017-08-03
US20160264567A1 (en) 2016-09-15
US10179782B2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
KR20170118166A (ko) 1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도
JP6735330B2 (ja) Ｔｒｐａ１調節因子として有用な置換複素環式スルホンアミド化合物
TWI664181B (zh) 做為ｐｄｅ２抑制劑之經取代的［１，２，４］三唑并［１，５－ａ］嘧啶－７－基化合物
JP2023093623A (ja) Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
BR112015027055B1 (pt) Bi-heteroarilas, usos das mesmas, e composição farmacêutica
JP7043483B2 (ja) 二環式プロリン化合物
CN108349935B (zh) 吡咯烷衍生物
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
JP7071959B2 (ja) スルホニルピリジルｔｒｐ阻害剤
KR20230027059A (ko) H－pgds를 저해하는 축환 화합물
TW201625608A (zh) 作為ｇｌｙｔ１抑制劑之經取代２，４，５，６－四氫吡咯并［３，４－ｃ］吡唑及４，５，６，７－四氫－２ｈ－吡唑并［４，３－ｃ］吡啶化合物
HK1251815B (zh) 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途
TW202206430A (zh) 作為trpv4拮抗劑之嘧啶-4(3h)-酮衍生物
HK1219478B (zh) 用作trpa1调节剂的取代的杂环磺酰胺化合物
HK1205106B (en) Substituted pyrimidine compounds and their use as syk inhibitors
HK1205106A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170914

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination